Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers.

Autor: Saulters EL; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom., Kennedy PT; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom., Carter RJ; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom., Alsufyani A; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom., Jones TM; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom., Woolley JF; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom., Dahal LN; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Jan 16; Vol. 4 (1), pp. 118-133.

A 5-microRNA signature derived from core binding factor-AML is predictive in adult and childhood AML.

Autor: Gabra MM; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Chow JT; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada., Kim T; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada., Son MH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Arruda A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Woolley JF; Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK., Zhang Z; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada., Salmena L; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: leonardo.salmena@utoronto.ca.

Publikováno v: Leukemia research [Leuk Res] 2022 Dec; Vol. 123, pp. 106968. Date of Electronic Publication: 2022 Oct 08.

Recent Progress in Interferon Therapy for Myeloid Malignancies.

Autor: Healy FM; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom., Dahal LN; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom., Jones JRE; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom., Floisand Y; Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom., Woolley JF; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.

Publikováno v: Frontiers in oncology [Front Oncol] 2021 Oct 29; Vol. 11, pp. 769628. Date of Electronic Publication: 2021 Oct 29 (Print Publication: 2021).

Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia.

Autor: Alsufyani A; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England, United Kingdom., Alanazi R; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England, United Kingdom., Woolley JF; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England, United Kingdom., Dahal LN; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, England, United Kingdom. L.N.Dahal@liverpool.ac.uk.; MRC Centre for Drug Safety Science, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England, United Kingdom.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2021 May; Vol. 19 (5), pp. 753-756. Date of Electronic Publication: 2021 Jan 26.

SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML.

Autor: Dzneladze I; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada.; Ontario Institute of Cancer Research, Toronto, Canada., Woolley JF; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada., Rossell C; Ontario Institute of Cancer Research, Toronto, Canada., Han Y; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Rashid A; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Jain M; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada., Reimand J; Department of Medical Biophysics, University of Toronto, Toronto, Canada.; Ontario Institute of Cancer Research, Toronto, Canada., Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, Canada., Salmena L; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada.

Publikováno v: PloS one [PLoS One] 2018 Feb 07; Vol. 13 (2), pp. e0191510. Date of Electronic Publication: 2018 Feb 07 (Print Publication: 2018).